HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Archive

All News

Every briefing, headline, and filing we've published, newest first.

Seaport, Hemab price IPOs, while Avalyn soars in Nasdaq debut
MoneyEndpoints News ↗
A trio of biotechs priced their IPOs on Thursday into Friday morning, setting the stage for their public tradi…
May 1, 2026
Lilly touts 'encouraging' early days for Foundayo obesity launch, even as GLP-1 pill appears to lag Novo's
MoneyFiercePharma ↗
As Eli Lilly gets off to the races with the launch of its flagship oral GLP-1 Foundayo, the Indianapolis drugm…
May 1, 2026
Teva inks $700M Emalex buyout to bag near-approval Tourette drug
DealsFierceBiotech ↗
Teva Pharmaceuticals has struck a deal to buy Emalex Biosciences for $700 million upfront, positioning the dru…
May 1, 2026
AstraZeneca Reverses UK Freeze with £300M Restart, Merck Still Holding Out
DealsBriefing
AstraZeneca resumes its shelved £300M UK expansion after rebate relief and a U.S.-U.K. pharma pact, signaling …
May 1, 2026
FDA flags concerns for AstraZeneca's camizestrant, Truqap ahead of advisory committee meeting
PipelineFiercePharma ↗
The FDA has released briefing documents detailing its concerns for AstraZeneca’s cancer drugs camizestrant and…
May 1, 2026
AbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisition
DealsFierceBiotech ↗
AbbVie has agreed to help finance a KRAS inhibitor from Kestrel Therapeutics in a deal that could hit up to $1…
May 1, 2026
Purdue Pharma’s Dissolution Approved, Closing Chapter in OxyContin Legal Case
PolicyBriefing
A judge approved Purdue Pharma’s criminal sentence, clearing the way for the company’s dissolution after years…
May 1, 2026
MoneyDrug Channels ↗
Today’s guest post comes from Cindy Baksh, Chief Product Officer at ConnectiveRx. Cindy explains that many gro…
May 1, 2026
STAT+: In her own words: Surgeon general nominee Nicole Saphier expresses enthusiasm and caution for MAHA
PeopleSTAT News ↗
Examining the past statements and writings of Trump's third surgeon general nominee, Dr. Nicole Saphier, on va…
Apr 30, 2026
PolicyAJMC ↗
Apr 30, 2026
Krazati fails confirmatory trial in colorectal cancer, putting approval at risk
PipelineEndpoints News ↗
Bristol Myers Squibb’s cancer drug Krazati has failed its confirmatory study in second-line colorectal cancer,…
Apr 30, 2026
House panel calls to ban China data from FDA drug trial applications
PolicyEndpoints News ↗
A powerful spending committee in Congress wants the FDA to ban the use of clinical trial data from China in fu…
Apr 30, 2026
Supreme Court questions how far generics makers can go with 'skinny label' drugs
PolicyEndpoints News ↗
WASHINGTON — Supreme Court justices gave a few hints about how they intend to rule in a divisive case for the …
Apr 30, 2026
STAT+: FDA wants to exclude weight loss drugs from a compounding list
PolicySTAT News ↗
FDA moves to remove semaglutide, tirzepatide, and liraglutide from its 503B compounding list, saying there's n…
Apr 30, 2026
Analysts focus on three programs in big year for Bristol Myers
MoneyEndpoints News ↗
Wall Street’s expectations for Bristol Myers Squibb’s upcoming slate of data readouts are reaching a fever pit…
Apr 30, 2026
STAT+: Cigna will exit ACA individual markets next year, adding to tumult for patients
PolicySTAT News ↗
ACA membership is tumbling after Congress failed to extend extra subsidies that helped people afford the cover…
Apr 30, 2026
Pfizer deals extend patent life for a top-selling rare disease drug
DealsPharmaVoice ↗
Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and …
Apr 30, 2026
Abortion Coverage Limitations in Medicaid and Private Insurance Plans
PolicyKFF Health News ↗
This brief reviews current federal and state policies on Medicaid and insurance coverage of abortion services …
Apr 30, 2026
Chiesi widens rare disease portfolio with $1.9bn KalVista buyout
DealsPharmaceutical Technology ↗
Chiesi will assume ownership of Ekterly, an on-demand pill approved for hereditary angioedema.…
Apr 30, 2026
Chiesi lays out $1.9B to bolster rare disease offerings with KalVista buyout
DealsFiercePharma ↗
As Ekterly nears the one-year anniversary of its approval, Chiesi Group is making moves to acquire the rare di…
Apr 30, 2026
Lilly pens $2.2B pact with Bezos-backed Profluent to work on recombinase-based gene editing
DealsFierceBiotech ↗
Eli Lilly’s latest attempt to strengthen its genetic medicine offering has seen the pharma team up with Proflu…
Apr 30, 2026
Avalyn’s $300M IPO Signals Renewed Appetite for Reformulation Plays
MoneyBriefing
Avalyn Pharma priced its Nasdaq debut at the top of range, raising $300M to push inhaled versions of existing …
Apr 30, 2026
Survey Offers Early Look at States’ Differing Approaches to Implementing Medicaid Work Requirements Amid Cost and Time Constraints and Uncertainty from Delayed Federal Guidance
PolicyKFF Health News ↗
A new KFF survey of state Medicaid officials and focus groups in eight states captures the different choices s…
Apr 30, 2026
STAT+: Supreme Court justices appear to signal ‘skinny labeling’ can survive
PolicySTAT News ↗
At Wednesday's argument, the justices did not appear to question whether skinny labeling is valid.…
Apr 29, 2026
← Newer Page 9 Older →
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.